Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Blue Trust Inc.

Blue Trust Inc. lifted its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 83.7% during the fourth quarter, HoldingsChannel reports. The firm owned 1,868 shares of the specialty pharmaceutical company’s stock after purchasing an additional 851 shares during the quarter. Blue Trust Inc.’s holdings in Jazz Pharmaceuticals were worth $230,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Wedge Capital Management L L P NC acquired a new position in Jazz Pharmaceuticals in the 3rd quarter worth $32,497,000. Pacer Advisors Inc. increased its position in shares of Jazz Pharmaceuticals by 15.3% during the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after acquiring an additional 278,465 shares during the last quarter. Cinctive Capital Management LP acquired a new position in shares of Jazz Pharmaceuticals in the third quarter worth about $14,277,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Jazz Pharmaceuticals by 135.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its stake in Jazz Pharmaceuticals by 47.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 268,783 shares of the specialty pharmaceutical company’s stock valued at $29,945,000 after purchasing an additional 86,768 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,253 shares of company stock valued at $890,594 in the last ninety days. Company insiders own 4.20% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on JAZZ. TD Cowen cut their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Morgan Stanley raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. Robert W. Baird upped their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research note on Monday, November 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $177.00.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $121.97 on Tuesday. The stock’s fifty day moving average is $122.69 and its two-hundred day moving average is $116.10. The stock has a market capitalization of $7.37 billion, a price-to-earnings ratio of 17.18, a PEG ratio of 0.90 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.